Patents by Inventor Michael Dickes

Michael Dickes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20220241415
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: September 10, 2021
    Publication date: August 4, 2022
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20210113694
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20190054171
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 21, 2019
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20180339046
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: August 7, 2018
    Publication date: November 29, 2018
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9950066
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 24, 2018
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9750808
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 5, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9738714
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 22, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9732152
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 15, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170158759
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: June 8, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170151329
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: June 1, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170145087
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170056498
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: April 11, 2016
    Publication date: March 2, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9327032
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 3, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 9302011
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: April 5, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9295725
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 29, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9289497
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 22, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9272042
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 1, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9272041
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 1, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20160030578
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9220781
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: December 29, 2015
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes